Lower brain glucose levels found in people with obesity, type 2 diabetes
Glucose levels are reduced in the brains of individuals with obesity and type 2 diabetes compared to lean individuals, according to a new Yale study. The finding might explain disordered eating behavior — and even a higher risk of Alzheimer’s disease — among obese and diabetic individuals, the researchers said.
How leptin, the ‘satiety hormone,’ reverses diabetes
Treatment with leptin, the hormone associated with fullness or satiety, reverses hyperglycemia in animals models of poorly controlled type 1 (T1D) and type 2 (T2D) diabetes by suppressing the neuroendocrine pathways that cause blood glucose levels to soar, a Yale-led team of researchers has found. The study appears in the Advance Online Publication of Nature Medicine.
Small: Yale study may help resolve bitter debate over low-cal sweeteners
Several studies in recent years have reported that low-calorie sweeteners in foods and beverages disrupt the human metabolism, promoting the development of diabetes and obesity. But other studies have found that consuming low-calorie drinks and food has little impact on metabolism and might actually aid in weight loss. A new study by Yale researchers published March 3 in the journal Cell Metabolism may help reconcile these conflicting findings.
Molecular ‘Doormen’ Open the Way to Potential Obesity Treatment
In obese individuals, cellular "doormen" open the gates far too wide in certain key fat cells, known as visceral fat cells, letting in too many carbohydrates without first burning off lipids. This leads to a ballooning of the size of visceral fat cells in the belly.
Want to Lose Weight? You Don’t Have to Do It Alone
A new Yale weight loss center aims to provide the entire continuum of care for patients with obesity, as a growing body of evidence has shown that weight loss—be it surgical or nonsurgical—also prolongs life, restores mobility, and lowers the risks of cancer, heart disease, liver disease, and other serious illnesses. “You start to get an idea of what a burden obesity is when you relieve patients of that burden. They were affected, literally, from head to toe,” says John Morton, MD, MPH.Source: Yale Medicine
Maternal acetaminophen use during pregnancy tied to excess weight in girls
Girls born to mothers who frequently used acetaminophen while pregnant may be more likely to be overweight at age 11 years compared with girls whose mothers did not use acetaminophen while pregnant, according to findings published in Obesity.Source: Endocrine Today
Yale-led Study Reveals Biology of Leptin, the Hunger Hormone
In a new study, Yale researchers offer insight into leptin, a hormone that plays a key role in appetite, overeating, and obesity. Their findings advance knowledge about leptin and weight gain, and also suggest a potential strategy for developing future weight-loss treatments, they said.
Pain and modifiable risk factors among overweight veterans who seek to lose weight
Robin Masheb, PhD, Senior Research Scientist in Psychiatry and Director of the Veterans Initiative for Eating and Weight at the VA Connecticut Healthcare System, is the senior author of a paper published in Appetite that examines the relationship between pain and and modifiable risk factors among overweight veterans who seek to lose weight.
National Public Radio (NPR) live interview on Where We Live with David Deroches and Lydia Brown: America’s Diet Craving
National Public Radio (NPR) live interview on Where We Live with David Deroches and Lydia Brown: America’s Diet CravingSource: National Public Radio (NPR) live interview on Where We Live with David Deroches and Lydia Brown: America’s Diet Craving
How obesity drives colon cancer in mice
Obesity, which is on the rise worldwide, has been linked to colon cancer but the mechanism has been a mystery. In a new study, Yale researchers and their co-authors have uncovered how obesity drives tumor growth in mice, revealing potential strategies to combat the disease.
Human insulin as safe and effective to treat type 2 diabetes as costlier insulin analogs
Patients with Type 2 diabetes who were treated with the newer generation of insulin analog drugs did not have substantially better outcomes than those treated with less costly human insulin, according to a study by Yale School of Medicine researchers and colleagues at Kaiser Permanente.